Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Conway

Showing results (41-50 of 146) with videos related to

Pageof 15
Sort By:
Harm Reduction Journal|October 1, 2023
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021Anthony Martinez, Tipu Khan, Douglas E Dylla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 10, 2008
Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutationsJesse D Raffa, Harout K Tossonian, Jason Grebely, et al.
The International Journal on Drug Policy|June 10, 2019
Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, CanadaJulie Holeksa, Tianna Magel, Arshia Alimohammadi, et al.
Antiviral Therapy|December 6, 2012
Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individualsMarina B Klein, Kathleen C Rollet, Mark Hull, et al.
Journal of Addiction Medicine|November 7, 2023
Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 PandemicKenneth Lee, Yue Zhao, Tazmin Merali, et al.
Canadian Journal of Gastroenterology & Hepatology|April 12, 2017
A Hepatitis C Educational Needs Assessment of Canadian Healthcare ProvidersReza Naghdi, Karen Seto, Carolyn Klassen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2004
Directly observed therapy for the management of HIV-infected patients in a methadone programBrian Conway, Jennie Prasad, Robert Reynolds, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|October 17, 2008
Directly observed therapy with azithromycin for skin and soft tissue infections in injection drug usersHarout K Tossonian, Brian Conway, Jesse D Raffa, et al.
The International Journal on Drug Policy|September 15, 2007
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infectionJason Grebely, Krista Genoway, Milan Khara, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|July 30, 2016
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentMark Hull, Stephen Shafran, Alex Wong, et al.
Pageof 15

Showing results (41-50 of 146) with videos related to

Sort By:
Pageof 15
Harm Reduction Journal|October 1, 2023
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021Anthony Martinez, Tipu Khan, Douglas E Dylla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 10, 2008
Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutationsJesse D Raffa, Harout K Tossonian, Jason Grebely, et al.
The International Journal on Drug Policy|June 10, 2019
Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, CanadaJulie Holeksa, Tianna Magel, Arshia Alimohammadi, et al.
Antiviral Therapy|December 6, 2012
Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individualsMarina B Klein, Kathleen C Rollet, Mark Hull, et al.
Journal of Addiction Medicine|November 7, 2023
Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 PandemicKenneth Lee, Yue Zhao, Tazmin Merali, et al.
Canadian Journal of Gastroenterology & Hepatology|April 12, 2017
A Hepatitis C Educational Needs Assessment of Canadian Healthcare ProvidersReza Naghdi, Karen Seto, Carolyn Klassen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2004
Directly observed therapy for the management of HIV-infected patients in a methadone programBrian Conway, Jennie Prasad, Robert Reynolds, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|October 17, 2008
Directly observed therapy with azithromycin for skin and soft tissue infections in injection drug usersHarout K Tossonian, Brian Conway, Jesse D Raffa, et al.
The International Journal on Drug Policy|September 15, 2007
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infectionJason Grebely, Krista Genoway, Milan Khara, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|July 30, 2016
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentMark Hull, Stephen Shafran, Alex Wong, et al.
Pageof 15